Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-Human, Ascending Dose Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV

Trial Profile

A Phase I, First-in-Human, Ascending Dose Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs SAR 441236 (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2018 Planned initiation date changed from 3 Dec 2018 to 18 Mar 2019.
    • 11 Dec 2018 Planned End Date changed from 30 Dec 2021 to 29 Jan 2021.
    • 11 Dec 2018 Planned primary completion date changed from 30 Dec 2021 to 29 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top